Upregulation of pro-inflammatory mediators contributes to -cell destruction and enhanced infiltration of immune cells into pancreatic islets during development of type 1 diabetes mellitus. In this study, we examined the regulatory effects and the mechanisms of action of celastrol against cytotoxicity and pro-inflammatory immune responses in the RINm5F rat pancreatic -cell line stimulated with a combination of interleukin-1 beta, tumor necrosis factor-alpha, and interferon-. Celastrol significantly restored cytokine-induced cell death and significantly inhibited cytokine-induced nitric oxide production. In addition, the protective effect of celastrol was correlated with a reduction in pro-inflammatory mediators, such as inducible nitric oxide synthase, cyclooxygenase-2, and CC chemokine ligand 2. Furthermore, celastrol significantly suppressed cytokine-induced signaling cascades leading to nuclear factor kappa B (NF-B) activation, including IB-kinase ( 
INTRODUCTION
The hallmark of type 1 diabetes mellitus (T1DM) is selective destruction of the insulin-producing pancreatic -cells via the inflammatory response (reviewed in [1] ). Various cytokines, such as interleukin-1beta (IL-1), interferon gamma (IFN-), and tumor necrosis factor alpha (TNF-), are produced from activated immune cells that infiltrate the islets during development of T1DM. These pro-inflammatory cytokines are important mediators that induce loss of pancreatic -cells (2, 3).
The molecular mechanisms underlying -cell destruction include upregulation of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), leading to enhanced production of nitric oxide (NO) and prostaglandin E2, respectively (2, 4) . In addition, various chemokines including CC chemokine ligand 2 (CCL2; monocyte chemoattractant protein-1), CXC chemokine ligand 8 (CXCL8; IL-8), and CXCL10 (IFN--induced protein-10) may contribute to -cell destruction by recruiting various immune cells into the pancreatic islets (5, 6) .
Nuclear factor kappa B (NF-B) signaling pathways predominantly regulate cell death and expression of various inflammatory mediators, such as iNOS, COX-2, and CCL2 in pancreatic -cells (7) . Cytokine stimulation initially activates the IB-kinase (IKK) complex, which consists of two kinase subunits (IKK and IKK) and the IKK/NEMO regulatory subunit. In turn, IKK rapidly phosphorylates IB on Ser32 and Ser36, resulting in its ubiquitination and subsequent proteasomal degradation (8) . NF-B dissociates from IB and translocates to the nucleus, where it activates gene transcription of inflammatory mediators.
Celastrol, a quinone methide triterpenoid, is a major constituent from Tripterygium wilfordii Hook with biological activities and has been used widely as a traditional medicine to control various inflammatory diseases (9) . Celastrol has anti-inflammatory activities in various inflammatory disease models (reviewed in [10] ). Although celastrol does not prevent diabetes in NOD mice, it transiently lowers blood glucose (11) . In addition, celastrol inhibits insulin resistance and diabetic nephropathy, possibly by inhibiting NF-B activity in a type 2 diabetic animal model (12) . Despite its beneficial effects on several diabetic conditions, the protective effect of celastrol on pancreatic -cells has not been determined. In this study, we investigated the regulatory effect of celastrol on cytokine-induced cell death, expression of pro-inflammatory mediators, and NF-B signaling cascades in RINm5F rat pancreatic -cells.
RESULTS

Celastrol reverses the cytotoxic effect of cytokines in RINm5F cells
We used the RINm5F rat pancreatic -cell line, which is a http://bmbreports.org BMB Reports . At 24 h after stimulation, cell viability was determined by the MTT assay. Results are expressed as mean ± standard deviation of three independent experiments. **P ＜ 0.01, ***P ＜ 0.001 compared to the cytokine-treated group. widely used model to study -cell death and inflammation. We first performed the MTT assay to evaluate the toxic effect of celastrol (Fig. 1A ) on RINm5F cells. As shown in Fig. 1B , celastrol did not significantly affect cell viability at the concentrations tested. We next examined the protective effect of celastrol on cytokine-induced cell death. RINm5F cells were exposed to various concentrations of celastrol in the presence of a combination of cytokines (5 ng/ml IL-1, 10 ng/ml TNF-, and 10 ng/ml IFN-) for 24 h, and cell viability was determined by the MTT assay. Treatment of RINm5F cells with cytokines alone resulted in about 62% cell death, compared to that in control cells. However, celastrol significantly increased cell viability in a dose-dependent manner (~56% at 0.05 g/ml), suggesting a protective effect of celastrol in cytokine-stimulated RINm5F cells (Fig. 1C) .
Celastrol inhibits iNOS and subsequent production of NO in cytokine-stimulated RINm5F cells
Inflammatory cytokines, such as IL-1, TNF-, and IFN-, exert toxic effects on pancreatic -cells by inducing iNOS expression and subsequent NO production (reviewed in [7] ). NO is a major mediator inducing cell death by altering mitochondrial metabolism and modifying proteins in pancreatic -cells (13) . To examine the regulatory effect of celastrol on cytokine-induced NO production, RINm5F cells were pretreated with various concentrations of celastrol for 1 h, stimulated with cytokines for 24 h, and then nitrite levels in the medium were evaluated using the Griess reaction. Stimulating RINm5F cells with cytokines markedly increased NO production, whereas a 1 h pretreatment with celastrol resulted in a significant reduction in NO levels in a dose-dependent manner in cytokine-stimulated RINSm5F cells ( Fig. 2A) . NO production in cytokine-stimulated RINm5F cells was attributed to upregulation of iNOS expression. Therefore, we investigated the inhibitory effects of celastrol on cytokine-induced iNOS expression. Cells pretreated with celastrol for 1 h were stimulated with cytokines, and iNOS mRNA and protein expression levels were measured by reverse transcription-polymerase chain reaction (RT-PCR) and Western blot analyses, respectively. As shown in Fig. 2B and 2C, celastrol significantly inhibited iNOS mRNA and protein expression in a dose-dependent manner in cytokine-stimulated RINm5F cells. These results support that inhibiting NO production with celastrol is correlated with inhibited iNOS expression in cytokine-stimulated RINm5F cells. These results contribute to the protective effect of celastrol against cytokine-induced cell death.
Celastrol inhibits cytokine-induced expression of COX-2 and CCL2 in RINm5F cells
Stimulating pancreatic -cells with cytokines, such as IL-1, TNF-, and IFN-, induces the expression of pro-inflammatory mediators, such as COX-2 and chemokines including CCL2, CXCL8, and CXCL10 (5, 6, 14) . These chemokines are implicated in the recruitment and activation of immune cells, such as monocytes and T cells, into pancreatic islets during development of T1DM (6, 14) . We further examined the effect of celastrol on the expression of pro-inflammatory mediators, such as COX-2, CCL2, CXCL8 and CXCL10, in cytokine-stimulated RINm5F cells. The cells were pretreated with celastrol for http://bmbreports.org , and -actin mRNA levels were determined by reverse transcription-polymerase chain reaction using specific primers. (B) COX-2 protein expression in cytokine-stimulated cells was measured by Western blot analysis using antibodies against COX-2 and -actin. (C) CCL2 production in the culture medium was determined using an enzyme-linked immunosorbent assay kit. Data are mean ± standard deviation of three experiments. ***P ＜ 0.001 compared to the cytokine-treated group. Fig. 3A , celastrol significantly decreased cytokine-induced COX-2 and CCL2 mRNA expression in a dose-dependent manner. However, no significant reduction in cytokine-induced CXCL8 and CXCL10 mRNA levels was observed when the cells were pretreated with celastrol. Celastrol inhibited cytokine-induced COX-2 protein expression, as determined by Western blot analysis (Fig. 3B) . We also analyzed the culture supernatants for levels of the CCL2 protein by enzyme-linked immunosorbent assay (ELISA). Similar to the CCL2 mRNA level, celastrol significantly inhibited cytokine-induced production of CCL2 in a dose-dependent manner (Fig. 3C) .
Celastrol inhibits cytokine-induced signaling cascades leading to NF-B activation in RINm5F cells
NF-B is a principal transcription factor for the expression of various proinflammatory mediators, such as iNOS, COX-2, and cytokines/chemokines (7, 15) . Signaling cascades leading to NF-B activation include IKK activation, IB degradation, and p65 phosphorylation (8) . We first investigated the effect of celastrol on cytokine-induced IKK/ activation. Total and phosphorylated forms of IKK in cell lysates were determined to evaluate the degree of IKK/ activation. As shown in Fig. 4A , celastrol significantly inhibited cytokine-induced IKK/ phosphorylation. Next, we evaluated the suppressive effect of celastrol on cytokine-induced downstream signaling cascades leading to NF-B activation after IKK activation. As shown in Fig.   4B , celastrol significantly suppressed IB degradation and p65 phosphorylation in cytokine-stimulated RINm5F cells. In addition, celastrol inhibited cytokine-induced p65 DNA-binding activity, as measured by electrophoretic mobility shift assay (EMSA) (Fig. 4C) . However, celastrol did not affect cytokine-induced signal transducer and activator of transcription 1 (STAT1) activation (Fig. 4D ). These findings suggest that suppressing signaling cascades leading to NF-kB activation is a mechanism by which celastrol inhibits expression of proinflammatory mediators, such as iNOS, COX-2 and CCL2, in cytokine-stimulated RINm5F cells.
DISCUSSION
The most common feature of T1DM is loss of pancreatic -cells via autoimmune responses (1) . When stimulated by inflammatory cytokines (e.g., IL-1, TNF-, and IFN-), insulinproducing pancreatic -cells express increased levels of iNOS and COX-2, as well as chemokines such as CCL2, which mediate destructive events in the pancreatic islets (3, 6) . Therefore, any interventions in the steps involved in cell death and http://bmbreports.org BMB Reports pro-inflammatory responses may provide a rationale for the development of therapeutic agents against T1DM. During pathogenic processes of inflammatory diseases including type 1 diabetes, macrophages and T cells infiltrate the pancreas, and produce various cytokines, such as IL-1, TNF-, and IFN-, which mediate selective -cell dysfunction and death (reviewed in [7] ). Previous reports have suggested that these cytokines induce cell death in synergistic fashion (reviewed in [16] ). The combination of IL-1, TNF-, and IFN- under our experimental conditions induced cell death in about 60% of RINm5F cells. However, cytokine-induced cell death was significantly inhibited by pretreatment with celastrol (Fig.  1C) , indicating its protective effect in cytokine-stimulated RINm5F cells. It has been suggested that cytokine-induced iNOS expression and subsequent NO production have functional correlations with the dysfunction and destruction of  cells (4) . We observed that celastrol suppressed iNOS expression and subsequent NO production in cytokine-stimulated RINm5F cells (Fig. 2) . In addition, celastrol significantly inhibited cytokine-induced COX-2 expression (Fig. 3A and B) . The inhibited iNOS and COX-2 expression may have contributed to the protective effect of celastrol against cytokine-induced cell death.
Chemokines, such as CCL2, CXCL8, CXCL10, are also mediators of -cell death by recruiting various immune cells into the pancreatic islets (5, 6) . Previous studies have demonstrated that increased CCL2, CXCL8, and CXCL10 expression levels are associated with disease progression in T1DM models (5, 6, 17) . Although resident macrophages and endothelial cells primarily secrete these chemokines,  cells release various chemokines including CCL2 upon stimulation by cytokines (reviewed in [16] ). We found that celastrol significantly decreased CCL2 production in cytokine-stimulated cells, whereas CXCL8 and CXCL10 levels were not lowered (Fig. 3) . The differential effect of celastrol on chemokine expression may be due to the distinct pathways leading to chemokine expression.
NF-B activation is involved in pro-apoptotic and inflammatory responses. Therefore, modulating NF-B activation is a promising strategy to develop therapeutic targets against T1DM (18) . Various stimuli including cytokines activate the IKK complex, consisting of IKK, IKK, and IKK/NEMO, which in turn activates downstream signaling cascades leading to NF-B activation (19) . As shown in Fig. 4A , celastrol significantly inhibited cytokine-induced IKK phosphorylation. A previous study revealed that celastrol suppresses IKK activity, possibly by directly targeting cysteine 179 in IKK (20) . Celastrol also suppressed cytokine-induced IB degradation, p65 phosphorylation, and DNA-binding activity of p65 NF-B (Fig. 4B and C) . Cytokines utilize diverse transcriptional factors other then NF-B, such as STAT1 and activator protein 1, leading to up-regulation of gene transcription related to -cell death (reviewed in [7] ). However, celastrol did not affect cytokine-induced STAT1 (Fig. 4D) or c-Jun activation (data not shown) under our experimental conditions. Taken together, these data suggest that celastrol exerts protective effects against cytokine-induced cell death and pro-inflammatory responses by suppressing NF-B signaling pathways
In conclusion, we provide evidence that celastrol regulated cytokine-induced cell death and pro-inflammatory responses by downregulating iNOS and COX-2, as well as chemokines such as CCL2 in RINm5F cells. Celastrol exerted its protective effects against cytokine-stimulated RINm5F cells by intervening in NF-B signaling pathways. Elucidating the mechanisms of action by which celastrol modulates dysfunction of pancreatic -cells may provide the molecular basis for developing therapeutic agents against T1DM.
MATERIALS AND METHODS
Cell culture and reagents
The RINm5F rat pancreatic -cell line was obtained from the American Type Culture Collection (Manassas, VA, USA) and maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, and antibiotics (100 U/ml penicillin G and 100 g/ml streptomycin) at 37 o C in a humidified incubator containing 5% CO2 and 95% air. IL-1, TNF-, and IFN- were obtained from R&D Systems (Minneapolis, MN, USA). Primary antibodies against iNOS, COX-2, and -actin were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Celastrol, HRP-conjugated anti-rabbit or goat antibodies were supplied by Sigma (St. Louis, MO, USA). All other reagents were from Sigma-Aldrich.
Cell viability assay
Cell viability was monitored by the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay with a slight modification (21) . Briefly, RINm5F cells were seeded at 1 × 10 5 cells/well in a 96-well plate. The cells were incubated with different concentrations of celastrol with or without a combination of cytokines (5 ng/ml IL-1, 10 ng/ml TNF-, and 10 ng/ml IFN-) for 24 h in serum-free media. MTT solution (1 mg/ml) was added to each well and incubated at 37 o C for 30 min. After the culture supernatants were removed, 0.5 mL isopropanol was added to dissolve the blue formazan crystals. Absorbance was measured at 570 nm with a microplate reader.
Nitrite determination
RINm5F cells seeded at 1 × 10 6 cells/well in a 6-well plate were cultured for 24 h in complete media. The cells were treated with celastrol for 1 h and then stimulated with cytokines (5 ng/ml IL-1, 10 ng/ml TNF-, and 10 ng/ml IFN-) for 24 h in serum-free media. The amount of nitrite in the culture medium was measured using the Griess reagent system (Promega, Madison, WI, USA) (21) .
Western blot analysis
Cellular or nuclear extracts were prepared in a lysis buffer (50 mM Tris-HCl, 150 ml NaCl, 1 mM EDTA, 1 mM PMSF, 1 g/ml leupeptin, 1 mM Na3VO4, 1 mM NaF, 1% NP-40, and 0.25% sodium deoxycholate). The protein concentrations in the samples were measured using the Bradford protein assay (Bio-Rad, Hercules, CA, USA). Proteins in samples were separated on 10% SDS-polyacrylamide gels and transferred to nitrocellulose membranes. The membranes were blocked with 10% nonfat dry milk in TBST buffer (137 mM NaCl, 20 mM Tris-HCl, pH 7.6, and 0.1% Tween 20) for 1 h, and incubated with primary antibodies at 4 o C overnight. After washing with TBST three times, the membranes were incubated with HRPconjugated primary antibodies for 2 h at room temperature. Immunoreactive proteins were detected by a chemiluminescence system (Amersham Life Sciences, Parsippany, NJ, USA) (22) .
RT-PCR analysis
Total cellular RNA was extracted from RINm5F cells using a Trizol reagent kit (Invitrogen, Gaithersburg, MD, USA), according to the manufacturer's instructions. cDNA was generated from total RNA (2 g) using 10,000 U of reverse transcriptase and 0.5 g/l oligo-(dT)15 primer (Promega, Madison, WI, USA) (23) . PCR amplification of cDNA was performed using the following sense and antisense primers (5'→3'): iNOS sense, TTG GGT CTT GTT AGC CTA GTC; iNOS antisense, TGT GCA GTC CCA GTG AGG AAC; COX-2 sense, CTG TAT CCC GCC CTG CTG GT; COX-2 antisense, ACT TGC GYY GAT GGC TG ; CCL2 sense, GTT GTT CAC AGT TGC TGC CT; CCL2 antisense, CTC TGT CAT ACT GGT CAC TT; CXCL8 sense, GAA GAT AGA TTG CAC CGA TG; CXCL8 antisense, CAT AGC CTC TCA CAC ATT TC; CXCL10 sense, CCG CGC CTA TCG CCA ATG AGC TGC GC; CXCL10 antisense, CTT GGG GAC ACC TTT TAG CAT CTT TTG G; beta-actin sense, GAC CGA GCG TGG CTA CAG C; beta-actin antisense, TGT CAG CGA TGC CTG GGT AC. PCR products were resolved on a 1% agarose gel and visualized with UV light after staining with ethidium bromide.
ELISA
RINm5F cells were pretreated with celastrol for 1 h and then stimulated with cytokines (5 ng/ml IL-1, 10 ng/ml TNF-, and 10 ng/ml IFN-) for 24 h. Culture supernatants were collected and analyzed for CCL2 production with an ELISA kit (R&D Systems), according to the manufacturer's instructions.
EMSA
RINm5F cells were pretreated with varying doses of celastrol for 1 h, and then stimulated with cytokines (5 ng/ml IL-1, 10 ng/ml TNF-, and 10 ng/ml IFN-) for 30 min. Nuclear extracts were prepared, and the EMSA was performed as described previously (24) . Nuclear extracts (10 g) were incubated with 32 P-end labeled double-stranded NF-B oligonucleotide (5'-AGT TGA GGG GAC TTT CCC AGG C-3'; Promega) in binding buffer (10 mM Tris-HCl, pH 8.0, 75 mM KCl, 2.5 mM MgCl2, 0.1 mM EDTA, 10% glycerol, 0.25 mM DTT, and 1 g of poly dI/dC) for 30 min. The DNA-protein complexes were analyzed by electrophoresis on a 6% native polyacrylamide gel in TBE buffer (89 mM Tris-HCl, 89 mM boric acid, and 2 mM EDTA). Then, the gels were dried and examined by autoradiography.
Statistical analysis
Results are expressed as mean ± standard deviation from at least three independent experiments. The values were evaluated by one-way analysis of variance, followed by Duncan's multiple range test using GraphPad Prism 4.0 software (GraphPad Software, Inc., San Diego, CA, USA). Null hypotheses of no difference were rejected if P values were less than .05.
